Charles River Laboratories International, Inc. Dividend History (CRL)
Charles River Laboratories International, Inc. does not pay dividends currently 😔
They might in the future, check back soon!
About Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. is a leading global provider of essential products and services that support pharmaceutical and biotechnology companies, as well as academic institutions and government agencies, in advancing their research and development efforts. Founded in 1947 by Dr. Henry L. Foster, the company has grown to become a trusted partner in the field of drug discovery and preclinical development. Headquartered in Wilmington, Massachusetts, Charles River has a global network of facilities and employs thousands of professionals dedicated to enabling scientific breakthroughs that improve human and animal health. With a strong commitment to quality and innovation, the company reported annual revenues of approximately $3.5 billion in recent years. Their comprehensive portfolio includes laboratory animal models, preclinical and clinical laboratory support services, and a range of research models and services. Charles River's mission is to deliver tailored solutions that drive the efficient and effective progress of clients' research programs from discovery through clinical support.
ICON Public Limited Company
IQVIA Holdings Inc.
The article discusses the potential impact of President Trump's policies on the stock market in 2025, noting that while a corporate tax rate cut could boost earnings, the growing deficit may make further tax cuts difficult. The author suggests the stock market's performance may not match the economic growth under the Trump administration.
Investing.com · Published on Mon Dec 02 2024
The global genetic toxicology testing market is projected to grow at a CAGR of 12.7% from 2024 to 2031, driven by the rising emphasis on genetic testing and the imposition of strict regulations to promote genetic toxicology testing.
Benzinga · Published on Thu Nov 28 2024The bioprocess validation market is expected to grow at a CAGR of 9.10% by 2031, driven by increasing demand for biopharmaceuticals and biologics, as well as advancements in biomanufacturing technology. However, the market faces challenges related to regulatory changes and compliance.
Benzinga · Published on Tue Nov 19 2024